Data Security for Pharma Companies: Safeguarding R&D and IP Data | Cyera Blog

Pharmaceutical organizations face elevated cyber risk from both financially motivated criminals and nation-state actors targeting R&D and IP; rapid cloud adoption has increased exposures through misconfigurations, data drift to unauthorized stores, overly permissive access, insider threats, and data mislabeling. The document reviews industry impacts and past incidents (e.g., Merck, Pfizer, Dedalus), cites high breach costs, and positions Cyera’s platform as a solution to discover, classify, and remediate sensitive data across cloud environments.